Abstract

The growing incidence of chronic kidney disease remains a global health problem. Obesity is a major risk factor for type-2 diabetes and renal impairment. Perirenal adiposity, by virtue of its anatomical proximity to the kidneys may cause kidney disease through paracrine mechanisms that include increased production of inflammatory cytokines. Although heme-oxygenase (HO) is cytoprotective, its effects on perirenal adiposity and diabetic nephropathy in Zucker-diabetic fatty rats (ZDFs) remains largely unclear. Upregulating the HO-system with hemin normalised glycemia, reduced perirenal adiposity and suppressed several pro-inflammatory/oxidative mediators in perirenal fat including macrophage-inflammatory-protein-1α (MIP-1α), endothelin (ET-1), 8-isoprostane, TNF-α, IL-6 and IL-1β. Furthermore, hemin reduced ED1, a marker of pro-inflammatory macrophage-M1-phenotype, but interestingly, enhanced markers associated with anti-inflammatory M2-phenotype such as ED2, CD206 and IL-10, suggesting that hemin selectively modulates macrophage polarization towards the anti-inflammatory M2-phenotype. These effects were accompanied by increased adiponectin, HO-1, HO-activity, atrial-natriuretic peptide (ANP), and its surrogate marker, urinary-cGMP. Furthermore, hemin reduced renal histological lesions and abated pro-fibrotic/extracellular-matrix proteins like collagen and fibronectin that deplete nephrin, an important transmembrane protein which forms the scaffolding of the podocyte slit-diaphragm allowing ions to filter but not massive excretion of proteins, hence proteinuria. Correspondingly, hemin increased nephrin expression in ZDFs, reduced markers of renal damage including, albuminuria/proteinuria, but increased creatinine-clearance, suggesting improved renal function. Conversely, the HO-blocker, stannous-mesoporphyrin nullified the hemin effects, aggravating glucose metabolism, and exacerbating renal injury and function. The hemin effects were less-pronounced in Zucker-lean controls with healthy status, suggesting greater selectivity of HO in ZDFs with disease. We conclude that the concomitant reduction of pro-inflammatory/oxidative mediators, macrophage infiltration and profibrotic/extracellular-matrix proteins, coupled to increased nephrin, adiponectin, ANP, cGMP and creatinine clearance may account for improved renal function in hemin-treated ZDFs. These findings suggest that HO-inducers like hemin may be explored against the co-morbidity of perirenal adiposity and diabetic nephropathy.

Highlights

  • Recent epidemiological data indicates that more than 1.6 billion adults worldwide are overweight and over 400 million are obese [1,2]

  • After a week of acclimation, the animals were randomly assigned to the following experimental groups: (A) controls (ZDF and Zucker lean (ZL)), (B) hemin-treated Zucker-diabetic fatty rats (ZDFs), (C) hemintreated ZL, (D) ZDF treated with hemin and the HO inhibitor, stannous mesoporphyrin (SnMP), (F) ZDF treated with SnMP alone, and (G) ZDF and ZL treated with vehicle dissolving hemin and SnMP

  • The co-administration of hemin and the HO-blocker, SnMP abolished the effect of hemin on perirenal adiposity and blood glucose, whereas treatment with SnMP alone aggravated perirenal adiposity and hyperglycemia suggesting a role of the HO system on the regulation of perirenal adiposity and glucose metabolism

Read more

Summary

Introduction

Recent epidemiological data indicates that more than 1.6 billion adults worldwide are overweight and over 400 million are obese [1,2]. Obesity is a major risk factor for insulin-resistant type-2 diabetes mellitus (T2D), dyslipidemia, hypertension and impaired renal function [3,4,5,6]. One of the common causes of morbidity and mortality in T1D and T2D patients is diabetic nephropathy, a micro-vascular complication of diabetes that may lead to endstage-renal-disease (ESRD) [7]. The growing incidence of chronic kidney disease is widely recognized as a global health problem. The prevalence and incidence of ESRD is greater in patients comorbid with obesity and diabetes [8]. Novel strategies that could simultaneously combat obesity, insulin resistant T2D and diabetic nephropathy are needed

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call